Q-omics provides the consensus-scored SNORA37 profile across patient tissues and cancer cell-line models. SNORA37 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORA37 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, SNORA37 RNA expression shows 8,039 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, BRCA, and UVM as cancer lineages where SNORA37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA37 survival associations across molecular data types. SNORA37 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA37 RNA expression–survival associations across cancer types. High SNORA37 expression shows unfavorable associations in KICH, CHOL, READ and LUSC, but favorable associations in STAD and HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORA37 RNA expression.
This table summarizes SNORA37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA37 shows lower tumor expression in LUAD, READ and THCA and higher tumor expression in BRCA and LUSC. The BRCA box plot shows higher SNORA37 RNA expression in tumor versus normal tissue (log2 FC = +0.515, t-test p < 0.001).
This table shows molecular features associated with SNORA37 in patient tissues and cancer cell lines. In patient samples, SNORA37 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
